Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- AstraZeneca Looks to Keep No.1 Spot in Japan Oncology Space, Driven by Bispecific Antibodies
February 7, 2025
- Kura/Kyowa Kirin’s AML Drug Inches Closer to FDA Filing on Positive PII Data
February 7, 2025
- Kyowa Kirin’s Profit Sags on R&D Spending, but Overseas Biz Fares Well
February 7, 2025
- Keytruda Extends Top Title Winning Streak to 16th Month in January: Encise
February 7, 2025
- Celltrion Set for 6 Biosimilar Filings in 2 Years, Sees Japanese Data Waiver as a Boon
February 6, 2025
- Izervay Filed for Conditional Approval in Japan: Astellas
February 6, 2025
- FRONTEO/Shionogi Eye FY2026 Approval for AI-Powered Cognitive Test
February 6, 2025
- Sumitomo Pharma CEO Hails Appointment of Parent Firm’s New President
February 5, 2025
- Astellas to Revamp Management in April, Consolidate R&D Functions
February 5, 2025
- Astellas to File Japan NDA for Izervay This Month
February 5, 2025
- Ono Axes ONO-2910 Peripheral Neuropathy Program and More
February 4, 2025
- Mochida President Hails Govt Initiatives to Drive Biosimilar Uptake
February 4, 2025
- Domestic Sites Approved for Meiji’s COVID Vaccine Kostaive
February 4, 2025
- ASKA to Boost Stake in Vietnam’s Ha Tay for Generic Biz Base
February 4, 2025
- Dato-DXd Gets EU Panel Backing for Breast Cancer: Daiichi Sankyo
February 4, 2025
- Daiichi Sankyo, Takeda Restricting Shipments of Mumps Vaccines
February 3, 2025
- Sumitomo Ups FY2024 Earnings Outlook, Now Expects Black Ink
February 3, 2025
- Shionogi to Bolster New Drug Development in China
February 3, 2025
- Daiichi Sankyo Assigns COO Okuzawa as CEO from April
February 3, 2025
- Datroway Now in PIII Study for Adjuvant NSCLC Setting: Daiichi Sankyo
February 3, 2025
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…